Clin Exp Vaccine Res.  2022 Jan;11(1):116-120. 10.7774/cevr.2022.11.1.116.

Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults

• Jo J
• Sanjaya A
• Pinontoan R
• Aruan M
• Wahyuni RM
• Viktaria V

• KMID: 2534934
• DOI: http://doi.org/10.7774/cevr.2022.11.1.116

Abstract

The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.

Keyword

COVID-19; CoronaVac vaccine; Anti-SARS-CoV-2 RBD antibody